PERSPECTA

News from every angle

Back to headlines

AusperBio Secures $120 Million Series C Funding for Hepatitis B Therapy Development

Biotechnology firm AusperBio has successfully closed a $120 million Series C financing round to advance its experimental hepatitis B treatment, AHB-137. The capital will support clinical development and potential commercialization efforts for the next-generation antiviral drug.

27 Aug, 17:40 — 28 Aug, 00:32
PostShare

The Story

Analyzing sources…

Source Diversity

Source Diversity

Moderate (27/100)
2 sources— more sources would strengthen this score15/33
Spectrum spread2/5 buckets covered8/33
Far L
Left1
Left (1)
Business Insider
Center1
Center (1)
morningstar
Right
Far R
Geographic diversity1 region4/34
US2
All sources from US region
Only 2 sources cover this story